Home › Funds › Tri Locum Partners LP › DFTX
Tri Locum Partners LP position in DFTX
DEFINIUM THERAPEUTICS INC · Health Care
Tri Locum Partners LP reported holding 162,996 shares of DFTX (DEFINIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$7.7M, representing 0.94% of its reported portfolio and ranking #19 among its reported holdings. Tri Locum Partners LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tri Locum Partners LP's DFTX position evolved
Tri Locum Partners LP first disclosed a stake in DFTX in Q1 2026 at 369,588 shares (US$7.0M). The position peaked in Q2 2026 at 162,996 shares, worth US$7.7M. Across 2 filings, Tri Locum Partners LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 162,996 shares valued at US$7.7M — a reduction of -206,592 shares quarter over quarter.. Notable position changes include a 56% trim in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 369.59K | $6.99M | New |
| Q2 2026 | 163.00K | $7.67M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DFTX and 13F data
DFTX (DEFINIUM THERAPEUTICS INC) is a Health Care company. 189 other funds we track also report a position in DFTX — the largest reported positions include Avoro Capital Advisors LLC (US$338.2M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$322.0M), Octagon Capital Advisors LP (US$138.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DFTX
- Avoro Capital Advisors LLC 7.19M sh · $338.17M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.85M sh · $322.00M · Q2 2026
- Octagon Capital Advisors LP 2.95M sh · $138.77M · Q2 2026
- Deep Track Capital, LP 2.75M sh · $129.36M · Q2 2026
- Commodore Capital LP 2.00M sh · $94.08M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.50M sh · $70.56M · Q2 2026
- Siren, L.L.C. 1.42M sh · $66.77M · Q2 2026
- Boxer Capital Management, LLC 998.50K sh · $46.97M · Q2 2026
- AWM Investment Company, Inc. 784.80K sh · $36.92M · Q2 2026
- ArrowMark Colorado Holdings LLC 564.07K sh · $26.53M · Q2 2026
- Catalio Capital Management, LP 562.67K sh · $26.47M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $25.87M · Q2 2026
More on Tri Locum Partners LP
FAQ
How long has Tri Locum Partners LP held DFTX?
Tri Locum Partners LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Tri Locum Partners LP's current position in DFTX?
As of Q2 2026, Tri Locum Partners LP holds 163.00K shares of DFTX (DEFINIUM THERAPEUTICS INC), valued at $7.67M, representing 0.94% of its reported portfolio and ranking #19.
Has Tri Locum Partners LP been buying or selling DFTX?
In the latest 13F filing (Q2 2026), Tri Locum Partners LP reduced its position in DFTX. The position peaked in Q2 2026 at 163.00K shares.
Which other funds hold DFTX?
Other major institutional holders of DFTX include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, among 189 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.